In the Canary Islands, a total of 81,754 boys and girls between the ages of 5 and 11 received the first dose of the coronavirus vaccine
To date, 52.4 percent of boys and girls ages 5 to 11 have received the first dose of the vaccine, and 40.5 percent have completed their vaccination schedule.
The Ministry of Health of the Government of the Canary Islands insists on the importance of vaccination against covid-19 among children aged 5 to 11 years as a tool to modulate the pandemic and reduce the risk of suffering from serious conditions in case of contracting an infection from SARS- CoV-2.
In the Canary Islands, a total of 81,754 boys and girls between the ages of 5 and 11 have received the first dose, representing 52.4 percent of the target population of this age group, while 40.5 percent already have the full model.
Pediatricians emphasize the importance of the 5- to 11-year-old population receiving the full guidance, given the safety of the vaccine and its approximately 91 percent effectiveness in preventing the development of the disease in children in this age group. Is indicated.
For this reason, they recommend that before the start of the course boys and girls are vaccinated to protect themselves and vulnerable people who may be in their family, social and educational environment.
While it is true that most minors suffer from covid-19 asymptomatically or with mild symptoms, some of them may have persistent symptoms. Approximately 30 percent of hospitalized minors had severe symptoms of this pathology. Children at potentially higher risk of severe covid-19 may benefit from vaccination as the best measure to prevent the disease in severe cases.
The aim of vaccination is to reduce the risk of severe forms of the disease, hospitalizations and death. It is also a way to prevent multisystem inflammatory syndrome (MIS) due to covid-19, an acute inflammatory reaction that can occur in the pediatric population without underlying diseases after a previous infection with SARS-CoV-2. The covid-19 vaccine can reduce the risk of hyperinflammatory syndrome up to 100 times.
People who have had a coronavirus infection may benefit from vaccination, as the immune response to future exposures to SARS-CoV-2 has been observed to be stronger and also broader compared to that achieved in humans , who have received a dose of the vaccine or who have just cleared the infection and with better protection against new variants and sub-variants.
In order for the school year to run smoothly, it is essential that children start their vaccination schedule if they have not yet done so, or complete it if they have received a single dose.
Access to vaccination
All boys and girls between the ages of 5 and 11 can request an appointment for a vaccine against coronavirus through the mobile application or website of the SCS MiCitaPrevia or by phone 012 (922 470 012 or 928 301 012).
Intervals between doses
The SNS Public Health Commission, at the request of the Vaccine Committee, ruled that the second dose interval should be eight weeks from the first dose.
Immunocompromised boys and girls between the ages of 5 and 11 years will receive an additional dose eight weeks after the second administered dose Children aged 5 to 11 years with a history of SARS-CoV-2 infection, regardless of the date of confirmation of infection, will be vaccinated as follows:
If the infection occurs before the administration of the vaccination, one dose of the vaccine will be administered from eight weeks after the diagnosis of the infection, with a minimum interval of four weeks.
If the infection is diagnosed after the first dose, the second dose will be given eight weeks after the diagnosis of the infection, maintaining a minimum interval of four weeks.
Except for children aged 5 to 11 years with high-risk conditions and on treatment with immunosuppressants, who will receive the second dose eight weeks after the last dose of the primary vaccination and regardless of whether they have passed the infection.
Also, on September 22, the Public Health Commission approved the document prepared by the Report on the Vaccination Program and Registry recommending the administration of a booster dose to minors between the ages of 5 and 11 with at-risk conditions.